Sarepta Therapeutics (SRPT) Tops Q4 EPS by 29c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Vifor Pharma said to have confirmed the purchase of Sarepta's (SRPT) Priority Review Voucher - Bloomberg
February 25, 2020 12:14 PM ESTVifor Pharma said to have confirmed the purchase of Sarepta's (NASDAQ: SRPT) Priority Review Voucher, as rumored earlier. - Bloomberg
... MoreSarepta Therapeutics (SRPT) May Have Sold Priority Review Voucher to Vifor - RBC
February 25, 2020 11:03 AM ESTRBC Capital analyst Brian Abrahams said there are signs that Sarepta Therapeutics (NASDAQ: SRPT) sold its Priority Review Voucher to Vifor Pharma.
"... we note a notice emerging just this morning from FTC providing clearance for an undisclosed transaction between SRPT and Vifor... More
